| Literature DB >> 27592379 |
Satomi Hisamoto1, Shinji Shimoda2, Kenichi Harada3, Sho Iwasaka4, Shinya Onohara5, Yong Chong6, Minoru Nakamura7, Yuki Bekki8, Tomoharu Yoshizumi9, Toru Ikegami10, Yoshihiko Maehara11, Xiao-Song He12, M Eric Gershwin13, Koichi Akashi14.
Abstract
Understanding the mechanisms of chronic inflammation in primary biliary cholangitis (PBC) is essential for successful treatment. Earlier work has demonstrated that patients with PBC have reduced expression of the anion exchanger 2 (AE2) on biliary epithelial cells (BEC) and deletion of AE2 gene has led to a PBC-like disorder in mice. To directly address the role of AE2 in preventing PBC pathogenesis, we took advantage of our ability to isolate human BEC and autologous splenic mononuclear cells (SMC). We studied the influence of hydrophobic bile acids, in particular, glycochenodeoxycholic acid (GCDC), on AE2 expression in BEC and the subsequent impact on the phenotypes of BEC and local inflammatory responses. We demonstrate herein that GCDC reduces AE2 expression in BEC through induction of reactive oxygen species (ROS), which enhances senescence of BEC. In addition, a reduction of AE2 levels by either GCDC or another AE2 inhibitor upregulates expression of CD40 and HLA-DR as well as production of IL-6, IL-8 and CXCL10 from BEC in response to toll like receptor ligands, an effect suppressed by inhibition of ROS. Importantly, reduced AE2 expression enhances the migration of autologous splenic mononuclear cells (SMC) towards BEC. In conclusion, our data highlight a key functional role of AE2 in the maintenance of the normal physiology of BEC and the pathogenic consequences of reduced AE2 expression, including abnormal intrinsic characteristics of BEC and their production of signal molecules that lead to the chronic inflammatory responses in small bile ducts.Entities:
Keywords: Autoimmune cholangitis; Cholangiocytes; Cytokine; Inflammation
Mesh:
Substances:
Year: 2016 PMID: 27592379 DOI: 10.1016/j.jaut.2016.08.006
Source DB: PubMed Journal: J Autoimmun ISSN: 0896-8411 Impact factor: 7.094